Exploring Indole‐1,3,4‐Thiadiazole Schiff Base Derivatives as Anticancer Agents: Design, Synthesis, In Vitro and In Silico Evaluation
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500231 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Umadevi Etikyala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Medicinal Chemistry Laboratory, Osmania University, Hyderabad, 500 076, India. Hauptthemen laut MEDLINE: Antineoplastic Agents, Thiadiazoles, Indoles, Drug Design. Die Arbeit nennt 35 Literaturangaben. Gefördert von: New Delhi; Council of Scientific and Industrial Research, Science and Engineering Research Board, DST-FIST MR.
Abstract (Originalsprache)
Cancer remains a major global health challenge, with resistance to existing therapeutic regimens underscoring the development of novel agents with improved efficacy and reduced toxicity. The indole and 1,3,4‐thiadiazole scaffolds are distinguished for their broad‐spectrum bioactivities, including anticancer properties. In this study, the synthesis and biological evaluation of a new series of indole‐1,3,4‐thiadiazole Schiff bases ( U1‐U31 ) designed to enhance anticancer efficacy is explored. In vitro evaluation demonstrates potent and selective cytotoxicity of several compounds, particularly U19 and U24 , against multiple cancer cell lines, with minimal toxicity to normal cells. Molecular docking and density functional theory studies demonstrate that these hybrid compounds effectively occupy the ATP‐binding sites of Pi3K and Akt proteins, exhibiting notable binding interactions comparable to the respective standard inhibitors. In addition, molecular dynamics simulation is performed to understand the conformational changes of the protein–ligand complex. Overall, the findings indicate that these novel indole‐1,3,4‐thiadiazole derivatives have selective inhibitory potency, making them promising leads for further anticancer drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Medicinal Chemistry Laboratory, Osmania University, Hyderabad, 500 076, India.
- Central Research Facility, National Institute of Technology Karnataka, Surathkal, Mangalore, 575025, India.
- School of Sciences, Woxsen University, Hyderabad, 502345, India.
- Department of Chemistry, Organic and Materials Chemistry Laboratory, National Institute of Technology Karnataka, Surathkal, Mangalore, 575025, India.
- Department of Chemistry, Osmania University College for Women, Hyderabad, 500095, India.
ORCID-Profile: Vijjulatha Manga
Förderung
- New Delhi; Council of Scientific and Industrial Research
- Science and Engineering Research Board
- DST-FIST MR
- ANRF
Zitieren
APA
Etikyala, U., Reddyrajula, R., Kumar Dalimba, U., Kokku, P., & Manga, V. (2025). Exploring Indole‐1,3,4‐Thiadiazole Schiff Base Derivatives as Anticancer Agents: Design, Synthesis, In Vitro and In Silico Evaluation. ChemMedChem. https://doi.org/10.1002/cmdc.202500231
Vancouver
Etikyala U, Reddyrajula R, Kumar Dalimba U, Kokku P, Manga V. Exploring Indole‐1,3,4‐Thiadiazole Schiff Base Derivatives as Anticancer Agents: Design, Synthesis, In Vitro and In Silico Evaluation. ChemMedChem. 2025. doi:10.1002/cmdc.202500231
BibTeX
@article{Etikyala2025,
author = {Etikyala, Umadevi and Reddyrajula, Rajkumar and Kumar Dalimba, Udaya and Kokku, Premalatha and Manga, Vijjulatha},
title = {Exploring Indole‐1,3,4‐Thiadiazole Schiff Base Derivatives as Anticancer Agents: Design, Synthesis, In Vitro and In Silico Evaluation},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500231}
}
EUVIMED